Physician profile
Sheila Jacobson
NPI 1881689073
$7,972.97
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,091 · 2020: $1,131 · 2021: $1,750 · 2022: $1,591 · 2023: $1,311 · 2024: $98.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $853.42 | 2019-2023 | Ajovy |
| Abbvie INC. | $629.71 | 2021-2023 | |
| Sk Life Science, INC. | $579.26 | 2020-2023 | |
| Kyowa Kirin, INC. | $474.41 | 2019-2023 | Nourianz |
| Ucb, INC. | $456.83 | 2019-2023 | Nayzilam, Briviact |
| Lilly USA, LLC | $425.45 | 2019-2023 | Emgality |
| Allergan, INC. | $395.18 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $363.92 | 2019-2023 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $325.01 | 2019-2022 | |
| Lundbeck LLC | $316.60 | 2020-2023 | Vyepti, Rexulti |
| Boston Scientific Corporation | $243.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $241.56 | 2023 | Rexulti, Nuedexta |
| Neurelis, INC. | $200.27 | 2020-2023 | Valtoco |
| Grifols USA, LLC | $200.24 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $184.31 | 2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.